Title: RARB associated with MSI, affects progression and prognosis of gastric cancer
Version: 2 Date: 27 Mar 2024
Reviewer's report:
In this study, we harnessed biotechnological analytics to isolate the RARB gene and delved
into its metabolic pathways through biosignature analysis. This investigation extended to
assessing RARB's impact on prognosis and immune infiltration levels in patients with gastric
cancer. To achieve this, we analyzed RARB expression in gastric cancer specimens via
immunohistochemistry and assessed its functional role in gastric cancer cell lines through gene
knockdown experiments. Our findings indicate that silencing RARB facilitates the proliferation
of gastric cancer cells, as evidenced by qRT-PCR, CCK-8, and colony formation assays.
The introduction section of this manuscript presently falls short in clearly defining the research
question, justifying the necessity of this study, and elucidating the importance of identifying
prognostic factors linked to RARB. Considering the extensive body of literature on H-related
genes and their association with cancer, including gastric cancer, it's imperative to expand the
introduction. This expansion should articulate the study's significance, especially in the context
of microsatellite instability (MSI) and prognostic target genes.
The methods employed in this research requires refinement for clarity and precision, ensuring
the reproducibility of the findings. The current draft's experimental methods section does not
adhere to the academic standards of scientific writing. It is crucial to rewrite this section, offering
a detailed and concise summary of the experimental procedures followed.
In the presentation of results, references are presently interwoven with findings to support the
latter. However, it is essential to delineate the study's outcomes explicitly, without embedding
them within the reference list.
The discussion section, mistakenly labeled as the conclusion, inadequately explores the specific
functions and mechanisms of RARB in gastric cancer. This section demands significant
expansion to thoroughly examine RARB's role in tumorigenesis and its potential as a target for
therapeutic intervention.
Lastly, the conclusion drawn about the oncogenic potential of RARB inhibitors, based on
cellular level assessments and their speculated reversal in invasive behavior due to the human
immune microenvironment, is overly simplistic. This simplification overlooks the complexities
inherent in cancer biology and the nuances of therapeutic application in humans. The conclusion,
as it stands, prematurely suggests RARB as a therapeutic target for MSI gastric cancer without
sufficient consideration of the broader implications. This necessitates a cautious rewrite of the
concluding remarks, summarizing the study's findings while acknowledging its limitations and
the prospects for future research to validate RARB's therapeutic potential.
Title: RARB associated with MSI, affects progression and prognosis of gastric cancer
Version: 2 Date: 27 Mar 2024
Reviewer's report:
In this study, we harnessed biotechnological analytics to isolate the RARB gene and delved
into its metabolic pathways through biosignature analysis. This investigation extended to
assessing RARB's impact on prognosis and immune infiltration levels in patients with gastric
cancer. To achieve this, we analyzed RARB expression in gastric cancer specimens via
immunohistochemistry and assessed its functional role in gastric cancer cell lines through gene
knockdown experiments. Our findings indicate that silencing RARB facilitates the proliferation
of gastric cancer cells, as evidenced by qRT-PCR, CCK-8, and colony formation assays.
The introduction section of this manuscript presently falls short in clearly defining the research
question, justifying the necessity of this study, and elucidating the importance of identifying
prognostic factors linked to RARB. Considering the extensive body of literature on H-related
genes and their association with cancer, including gastric cancer, it's imperative to expand the
introduction. This expansion should articulate the study's significance, especially in the context
of microsatellite instability (MSI) and prognostic target genes.
The methods employed in this research requires refinement for clarity and precision, ensuring
the reproducibility of the findings. The current draft's experimental methods section does not
adhere to the academic standards of scientific writing. It is crucial to rewrite this section, offering
a detailed and concise summary of the experimental procedures followed.
In the presentation of results, references are presently interwoven with findings to support the
latter. However, it is essential to delineate the study's outcomes explicitly, without embedding
them within the reference list.
The discussion section, mistakenly labeled as the conclusion, inadequately explores the specific
functions and mechanisms of RARB in gastric cancer. This section demands significant
expansion to thoroughly examine RARB's role in tumorigenesis and its potential as a target for
therapeutic intervention.
Lastly, the conclusion drawn about the oncogenic potential of RARB inhibitors, based on
cellular level assessments and their speculated reversal in invasive behavior due to the human
immune microenvironment, is overly simplistic. This simplification overlooks the complexities
inherent in cancer biology and the nuances of therapeutic application in humans. The conclusion,
as it stands, prematurely suggests RARB as a therapeutic target for MSI gastric cancer without
sufficient consideration of the broader implications. This necessitates a cautious rewrite of the
concluding remarks, summarizing the study's findings while acknowledging its limitations and
the prospects for future research to validate RARB's therapeutic potential.
Please review this paper.
user
Title: RARB associated with MSI, affects progression and prognosis of gastric cancer
Version: 2 Date: 27 Mar 2024
Reviewer's report:
In this study, we harnessed biotechnological analytics to isolate the RARB gene and delved
into its metabolic pathways through biosignature analysis. This investigation extended to
assessing RARB's impact on prognosis and immune infiltration levels in patients with gastric
cancer. To achieve this, we analyzed RARB expression in gastric cancer specimens via
immunohistochemistry and assessed its functional role in gastric cancer cell lines through gene
knockdown experiments. Our findings indicate that silencing RARB facilitates the proliferation
of gastric cancer cells, as evidenced by qRT-PCR, CCK-8, and colony formation assays.
The introduction section of this manuscript presently falls short in clearly defining the research
question, justifying the necessity of this study, and elucidating the importance of identifying
prognostic factors linked to RARB. Considering the extensive body of literature on H-related
genes and their association with cancer, including gastric cancer, it's imperative to expand the
introduction. This expansion should articulate the study's significance, especially in the context
of microsatellite instability (MSI) and prognostic target genes.
The methods employed in this research requires refinement for clarity and precision, ensuring
the reproducibility of the findings. The current draft's experimental methods section does not
adhere to the academic standards of scientific writing. It is crucial to rewrite this section, offering
a detailed and concise summary of the experimental procedures followed.
In the presentation of results, references are presently interwoven with findings to support the
latter. However, it is essential to delineate the study's outcomes explicitly, without embedding
them within the reference list.
The discussion section, mistakenly labeled as the conclusion, inadequately explores the specific
functions and mechanisms of RARB in gastric cancer. This section demands significant
expansion to thoroughly examine RARB's role in tumorigenesis and its potential as a target for
therapeutic intervention.
Lastly, the conclusion drawn about the oncogenic potential of RARB inhibitors, based on
cellular level assessments and their speculated reversal in invasive behavior due to the human
immune microenvironment, is overly simplistic. This simplification overlooks the complexities
inherent in cancer biology and the nuances of therapeutic application in humans. The conclusion,
as it stands, prematurely suggests RARB as a therapeutic target for MSI gastric cancer without
sufficient consideration of the broader implications. This necessitates a cautious rewrite of the
concluding remarks, summarizing the study's findings while acknowledging its limitations and
the prospects for future research to validate RARB's therapeutic potential.
assistant